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OBJECTIVES This study aimed to evaluate the role of gene expression for predicting myocardial recovery
in recent-onset cardiomyopathy.
BACKGROUND Apoptosis may limit ventricular recovery. We examined the myocardial expression of Fas, Fas
ligand (FasL), tumor necrosis factor (TNF)-alpha, and TNF receptor 1 (TNFR1), and
myocardial recovery in patients from the multicenter Intervention in Myocarditis and Acute
Cardiomyopathy (IMAC) study.
METHODS Endomyocardial biopsy samples were obtained in 20 patients with recent-onset (6 months)
idiopathic dilated cardiomyopathy (left ventricular ejection fraction [LVEF] 0.40). The
LVEF was assessed at baseline and at 6 and 12 months by nuclear scans. Myocardial
expression was assessed by ribonuclease (RNase) protection, normalized to a constitutively
active gene (glyceraldehydes 3-phosphate dehydrogenase [GAPDH]) and reported as percent
GAPDH expression. The change in LVEF at 6 and 12 months was compared by tertiles of
expression.
RESULTS For all patients (14 men, 6 women; age 46.5  10.7 years), the mean LVEF was 0.28  0.05
at baseline and 0.40 0.14 at six months. Patients in the highest tertile of Fas expression had
minimal improvement at six months (EF  0.03  0.05) when compared with the
intermediate (EF 0.10 0.13) and lowest tertiles (EF 0.21 0.11, change in LVEF
by tertile, p  0.006). A similar relationship was seen with TNFR1 expression (highest
tertile, EF  0.06  0.07; lowest tertile, EF  0.21  0.11, p  0.02). In contrast with
Fas and TNFR1, expression of TNF-alpha and FasL did not predict recovery of LV function.
CONCLUSIONS In cardiomyopathy of recent onset, increased expression of Fas and TNFR1 was associated
with minimal recovery of LV function. Apoptosis limits myocardial recovery, and represents
a potential target for therapeutic intervention. (J Am Coll Cardiol 2005;46:1036–42)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.067© 2005 by the American College of Cardiology Foundation
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tor patients presenting with recent-onset dilated cardiomy-
pathy, clinical outcomes and the degree of myocardial
ecovery vary widely. Significant improvement in left ven-
See page 1043
ricular ejection fraction (LVEF) is seen in 30% to 40% of
atients (1,2), whereas the remainder of patients are left
ith persistent left ventricular dysfunction and congestive
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ccepted May 3, 2005.eart failure (3). Although cellular inflammation is evident
n biopsy in a subset of patients (1), histology on endomyo-
ardial biopsy is generally not predictive of outcome. In fact,
here are few reliable predictors of subsequent recovery of
entricular function.
In patients with chronic heart failure, loss of myocytes
aused by apoptosis or programmed cell death results in
rogressive myocardial dysfunction (4,5). Fas is a trans-
embrane cell surface receptor that plays a critical role in
poptosis (6). When engaged by the signaling peptide Fas
igand (FasL), the receptor initiates a cascade that leads to
roteolysis and programmed cell death. Other cytokines are
mportant in this pathway, and the interaction of tumor
ecrosis factor (TNF)-alpha and its receptor, TNFR1, also
eads to apoptosis. Patients with progressive left ventricular
ysfunction and chronic heart failure have elevated levels of
oluble Fas that correlate with prognosis (7–11). In addi-
ion, levels of serum FasL are increased in patients with
yocarditis and correlate with severity of heart failure (11).
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September 20, 2005:1036–42 Fas Expression in Recent-Onset Cardiomyopathyhe impact of myocardial expression of mediators of apo-
tosis on myocardial recovery has not been previously
valuated in cardiomyopathy of recent onset.
We examined the myocardial expression of Fas and FasL,
heir relationship to expression of the proinflammatory
ytokines TNF-alpha and its receptor TNFR1, and their
mpact on subsequent myocardial recovery in a series of
atients with recent-onset cardiomyopathy.
ETHODS
atients. Endomyocardial biopsy samples were obtained in
0 patients with recent-onset idiopathic dilated cardiomy-
pathy from the right ventricle using standard techniques.
ineteen patients were recruited from the gene expression
ubstudy of the Intervention in Myocarditis and Acute
ardiomyopathy (IMAC) study (12), and the remaining
atient was from the previous pilot study (13). All patients
ad an LVEF 0.40, were within six months of their onset
f cardiac symptoms, and had an extensive evaluation
ncluding right heart catheterization and right ventricular
iopsy. Baseline assessment of LVEF by radionuclide scan
as performed, and LVEF was reassessed at 6 and 12
onths after presentation.
ene expression. Samples were immediately frozen in
iquid nitrogen and stored at 80°C until analysis. To
easure myocardial gene expression, total ribonucleic acid
RNA) was extracted from frozen tissues by using an acid
uanidium thiocyanate-phenol-chloroform method. A
ommercially available multi-probe RNase protection assay
it (Riboquant, PharMingen, San Diego, California) was
sed to evaluate transcript levels, with the assay performed
ccording to the manufacturer’s protocol. The value of each
ybridized probe was quantified by the PhosphoImager
sing ImageQuant software (Molecular Dynamics, Sunny-
ale, California) and normalized to that of a constitutively
ctive gene, glyceraldehydes 3-phosphate dehydrogenase
GAPDH) included in each template set as an internal
ontrol (arbitrarily set as  1). Myocardial levels of mRNA
or TNF-alpha, TNF receptor-1 (TNFR1), Fas, FasL, and
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
FasL  Fas ligand
FLICE  Fas-associated death domain-like
interleukin-1-converting enzyme
GAPDH  glyceraldehydes 3-phosphate dehydrogenase
IMAC  Intervention in Myocarditis and Acute
Cardiomyopathy study
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RNA  ribonucleic acid
TNF  tumor necrosis factor
TNFR  tumor necrosis factor receptoras-associated death domain-like interleukin-1-beta- 0onverting enzyme (FLICE) were then expressed as per-
ents of GAPDH mRNA level.
tatistical analysis. Statistical analysis was performed us-
ng the statistics software SPSS (SPSS Inc., Chicago,
llinois). Results are presented as mean values  standard
eviation. Patients were grouped into tertiles based on gene
xpression of Fas, FasL, TNF, and TNFR1. For continuous
ariables, assessment of significant differences between or-
ered tertile means was performed by one-way analysis of
ariance; significance of a linear trend across ordered means
s reported. An exact version of the Mantel-Haentzsel trend
est was used to compare distributions of all categorical
ariables by ordered tertiles. Pearson’s correlation coefficient
as used as a measure of linear association between two
ariables. Differences were considered significant at a value
f p  0.05.
ESULTS
linical characteristics. The 20 patients (14 men and 6
omen) had a mean age of 46.5  10.7 years and a New
ork Heart Association (NYHA) functional class I/II/
II/IV  4/9/7/0 (Tables 1 and 2). The LVEF at baseline
as 0.28  0.05, and the left ventricular end diastolic
imension was 6.5  0.9 cm. Their mean pulmonary
apillary wedge pressure was 11.9  7.8 mm Hg, cardiac
utput and cardiac index were 5.3  1.5 l/min and 2.6 
.6 l/min, respectively, pulmonary artery pressure was
1.2  9.1 mm Hg, and mean right atrial pressure was
.3  3.6 mm Hg. No patient was febrile at the time of
ntry. Nine of 20 patients (45%) gave a history of a
ignificant febrile illness within the past year (mean
uration between febrile illness and study entry, 5.9 
.6 months). All had a normal white blood cell count at
ime of entry (mean, 6.9  1.5; range, 4.9 to 10.0 
03/mm3). Endomyocardial biopsies were interpreted as
egative for myocarditis in 19 of 20 patients, and
orderline myocarditis in one individual. Medical therapy
t time of presentation and right ventricular biopsy
ncluded angiotensin-converting enzyme inhibitors
ACEIs) in 19 (95%) and an angiotensin receptor antag-
nist in the remaining subject. Beta-adrenergic receptor
ntagonists were utilized in three patients (15%) at
aseline and at 6- (30%) and 12-month follow-up.
aseline gene expression and subsequent improvements
n LVEF. The mean expression levels of TNF-alpha and
NFR1 (55 kD) were 0.12  0.04% and 1.87  0.43% of
APDH transcript levels. The expression levels for the
poptosis genes were: Fas, 0.22  0.07%; FLICE, 0.15 
.05%; and FasL, 0.008  0.007%. There was a significant
orrelation between myocardial expression of Fas and TNF-
lpha (r  0.76, p  0.01, Fig. 1) and between expression
f Fas and TNFR1 (r  0.66, p  0.05).
Overall, there was significant recovery of left ventricular
unction at the six-month reassessment (baseline LVEF,
.28  0.05; six-month LVEF, 0.40  0.14; p  0.01),
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Fas Expression in Recent-Onset Cardiomyopathy September 20, 2005:1036–42hich was maintained at the 12-month assessment (LVEF
t 12 months, 0.40  0.13, compared with baseline, p 
.01; compared with six months, p  NS; Tables 3 and 4).
significant negative correlation exists between baseline
yocardial expression of Fas and the subsequent change in
VEF at 6 months (r  0.54, p  0.01) and 12 months
r  0.50, p  0.02). In contrast, there was no significant
orrelation between baseline expression of TNF-alpha and
he change in LVEF (6 months: r  0.37, p  0.10; 12
onths: r  023, p  0.32).
ertile analysis. The clinical characteristics by Fas tertile
re listed in Table 1. Patients were divided into tertiles on
he basis of Fas expression into those with low (Fas
able 1. Baseline Characteristics by Tertiles of Fas Expression
Total
(n  20)
Low
(n 
ge (yrs) 46  11 42 
Male 70 4
YHA functional class (I/II/III) 4/9/7 0/3
onths of symptoms 2.2  1.6 2.0 
VEF, baseline 0.28  0.05 0.27 
eak MVO2 21.5  4.7 20.5 
VEDD (cm) 6.6  0.9 6.2 
CWP (mm Hg) 12  8 10 
ardiac output (l/min) 5.3  1.5 4.8 
A (mm Hg) 4  4 4 
CEI or ARB 100% 10
eta-blockers 15% 1
P systolic, baseline 116  16 123 
P systolic, 6 months 120  20 129 
P systolic, 12 months 117  16 120 
P diastolic, baseline 74  10 77 
P diastolic, 6 months 76  13 76 
P diastolic, 12 months 74  11 70 
CEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blo
eft ventricular ejection fraction; MVO2  maximum oxygen consumption (cc/kg/mi
apillary wedge pressure; RA  right atrial pressure.
Table 2. Baseline Characteristics by Tertiles of
Low
TNFR1
(n  7)
Age (yrs) 43  13
% Male 43
NYHA functional class (I/II/III) 0/2/5
Months of symptoms 2.1  1.7
LVEF, baseline 0.28  0.06
Peak MVO2 20.2  3.1
LVEDD (cm) 6.2  0.7
PCWP (mm Hg) 8  5
Cardiac output (l/min) 4.2  1.8
RA (mm Hg) 3  3
ACEI or ARB 100%
Beta-blockers 14%
BP systolic, baseline 116  27
BP systolic, 6 months 125  26
BP systolic, 12 months 117  13
BP diastolic, baseline 73  14
BP diastolic, 6 months 74  13
BP diastolic, 12 months 71  8TNFR1  tumor necrosis factor receptor 1; other abbreviations asranscript level  0.22% of GAPDH, n  7), intermediate
0.22% to 0.26%, n 7) and high expression (0.26%, n
). Patients with high Fas expression had minimal improve-
ent in LVEF (change in LVEF at six months  0.03 
.05), those with intermediate expression had a greater
ncrease (0.10  0.13), whereas patients with the lowest
xpression had the greatest improvement (0.21  0.11;
omparison change in LVEF by tertile, p  0.006; Fig. 2).
his difference in LV recovery based on Fas expression at
aseline persisted at 12 months (change in LVEF by tertiles
ow/intermediate/high  0.22  0.13/0.09  0.13/0.02 
.06, p  0.004, Fig. 3). Fas expression was inversely
ssociated with NYHA functional class (mean Fas expres-
Intermediate Fas
(n  7)
High Fas
(n  6) p Value
46  12 52  3 NS
71 100 0.04
1/3/3 3/3/0 0.01
2.4  1.7 2.2  1.5 NS
0.29  0.07 0.28  0.05 NS
21.8  5.7 22.3  5.4 NS
6.6  0.9 6.9  1.0 NS
13  9 12  6 NS
5.2  1.2 6.2  1.5 NS
5  4 4  3 NS
100% 100% NS
29% 0% NS
109  14 118  10 NS
110  14 122  19 NS
116  20 114  14 NS
67  7 79  10 NS
71  11 81  17 NS
74  14 78  10 NS
P  blood pressure; LVEDD  left ventricular end-diastolic dimension; LVEF 
 not significant; NYHA  New York Heart Association; PCWP  pulmonary
FR1 Expression
Intermediate
TNFR1
(n  7)
High
TNFR1s
(n  6) p Value
50  3 47  13 NS
71 100 0.04
1/5/1 3/2/1 0.01
2.7  1.5 1.8  1.7 NS
0.29  0.05 0.27  0.06 NS
21.3  6.4 23.2  4.9 NS
6.6  0.9 6.9  1.0 NS
14  8 14  9 NS
6.0  1.6 6.0  1.6 0.03
5  4 6  4 NS
100% 100% NS
14% 17% NS
116  10 115  8 NS
116  14 117  21 NS
122  9 111  24 NS
75  9 74  6 NS
76  11 77  17 NS
81  11 71  12 NSFas
7)
13
3
/4
1.8
0.04
3.2
0.7
8
1.8
4
0%
4%
24
26
12
10
12
9
cker; BTNin Table 1.
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September 20, 2005:1036–42 Fas Expression in Recent-Onset Cardiomyopathyion in NYHA class I/II/III  0.27  0.11/0.23 
.07/0.18  0.06, p  0.03). The NYHA functional class
eflects functional status at the time of enrollment, and the
our class I patients were all class II to III at the time of
nitial presentation.
For TNFR1, patients were divided into low (TNFR1
ranscript level 1.67% of GAPDH, n  7), intermediate
1.67% to 2.0%, n  7), and high expression (2.0%, n 
). Similar tertile analysis showed that high TNFR1 expres-
ion was associated with a limited increase in LVEF and low
NFR1 expression predicted greater improvement in
VEF at 6 and 12 months (change in LVEF by TNFR1
xpression tertiles at 6 months, low/intermediate/high 
.21  0.11/0.08  0.13/0.06  0.07, p  0.02, Fig. 4; 12
onths  0.22  0.12/0.08  0.12/0.04  0.10, p  0.01,
ig. 5). Tertile analyses of TNF-alpha, FasL, and FLICE
id not predict subsequent changes in LVEF.
Male gender was associated with a higher expression of
as and TNFR1 (p 0.04). Tertile analysis was repeated in
he male subset (n 14). Fas and TNFR1 tertiles remained
redictive of LV improvement at 6 months (Fas, p  0.02;
NFR1, p  0.08) and 12 months (Fas, p  0.004;
igure 1. Relationship between baseline myocardial tumor necrosis fact
-phosphate dehydrogenase (GAPDH) expression. Correlation of Fas and
able 3. Left Ventricular Ejection Fraction by Fas Tertile
Total
(n  20)
Low Fa
(n  7)
VEF, baseline 0.28  0.05 0.27  0.
VEF, 6 months 0.40  0.14 0.49  0.
VEF, 12 months 0.40  0.13 0.49  0.
hange in EF, 6 months 0.12  0.13 0.22  0.
hange in EF, 12 months 0.12  0.13 0.22  0.bbreviations as in Table 2.NFR1, p  0.01) when evaluated in male patients,
uggesting that differences in gender did not underlie
pparent differences in the tertiles overall.
mpact of medical therapy on LV recovery. Beta-blocker
herapy was used by 3 of 20 (15%) of patients at baseline, 5
25%) at 6 months, and 6 (30%) at 12 months. The low
ercentage of patients on beta-blockers was reflective of
volving practice guidelines during the time of enrollment
1996 to 1998). The percentage of patients on beta-blockers
y Fas tertile (low, intermediate, high) was not significantly
ifferent at baseline (Tables 1 and 2) or at 6 or 12 months.
he mean LVEF was significantly higher for patients on
eta-blockers at 12-month follow-up, (n  6, LVEF 
.50  14) when compared with those not on therapy (n 
4, LVEF  0.35  0.10, p  0.01). Therefore, to ensure
hat beta-blocker therapy was not acting as a confounder,
nalysis of the change in EF by Fas tertile was repeated
xclusively in patients not treated with beta-blockers during
ollow-up. Even in this smaller cohort (n  14), high Fas
xpression remained significantly linked to less improve-
ent in LVEF for both the 6-month (p  0.014) and the
2-month (p  0.017) end points. For the small subset (n
NF)-alpha and Fas gene expression, noted as percent glyceraldehydes
F expression: r  0.76, p  0.01.
Intermediate Fas
(n  7)
High Fas
(n  6) p Value
0.29  0.07 0.28  0.05 NS
0.39  0.16 0.32  0.05 0.03
0.39  0.14 0.30  0.07 0.006
0.10  0.13 0.03  0.05 0.006
0.09  0.13 0.02  0.06 0.004s
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Fas Expression in Recent-Onset Cardiomyopathy September 20, 2005:1036–426) on beta-blockers, the improvement in LVEF seemed
o be greater for patients on beta-blockers from the lowest
as tertile (n  3, increase in LVEF  0.30  0.10) than
or those in higher tertiles of Fas expression (n  3, change
n EF  0.12  0.21); however, this was not significant
iven the limited number of patients.
All patients were on ACEI therapy at study entry. The
CEI dose was increased in 8 of 20 patients (40%) during
ollow-up. The number of patients with an increase in
CEI therapy was similar in all Fas tertiles (43%, 43%,
3%, p  0.92), and was not associated with increased
VEF (ACE increased, n  8; LVEF  0.40  0.16; not
ncreased, LVEF  0.40  0.11; p  0.92). Although
tatistical power was limited in the smaller subsets, tertiles
f Fas expression seemed predictive of subsequent LV
ecovery in both groups for the 6-month (ACE not in-
reased, p 0.05; ACE increased, p 0.10) and 12-month
nd points (ACE not increased, p  0.08; ACE increased,
 0.02).
ISCUSSION
n this study of patients with recent-onset cardiomyopathy,
atients with lower expression of the receptors that initiate
igure 2. Box plot of distribution change in left ventricular ejection
raction (LVEF) at six months by tertiles of baseline Fas expression. Solid
lack lines  median; rectangles  quartile range; whiskers  total
Table 4. Left Ventricular Ejection Fraction by
Low
TNFR1
(n  7)
LVEF, baseline 0.29  0.06
LVEF, 6 months 0.50  0.11
LVEF, 12 months 0.51  0.08
Change in EF, 6 months 0.21  0.11
Change in EF, 12 months 0.22  0.12
Abbreviations as in Table 2.ange. Higher Fas expression is associated with less improvement in LVEF
t six months, p  0.006.
b
whe apoptosis pathway, Fas and TNFR1, had significantly
ore LV recovery during subsequent follow-up, with mean
mprovements in LVEF of more than 20 EF units at 6 and
2 months. In contrast, patients with the highest Fas and
NFR1 expression had minimal improvements of LVEF
vident during the course of the study. This analysis
uggests that activation of apoptotic pathways may limit
yocardial recovery in this disorder, and that the levels of
as and TNFR1 expression may be useful clinical predictors
f the potential for subsequent LV recovery.
In the IMAC study of acute cardiomyopathy and myo-
arditis, biopsy status, hemodynamic assessment, and met-
bolic stress testing all failed to predict subsequent improve-
ents in LVEF (12). In cardiomyopathy of recent onset,
he percentage of patients with biopsy-proven myocarditis
n published series is variable, with as few as 10% showing
nflammatory infiltrates (14). Evidence of cellular inflam-
ation on biopsy does not seem to predict clinical outcome
1). In fact, patients with fulminant myocarditis seem to
ave a significant chance of complete recovery (15). For
atients with recent-onset cardiomyopathy, the utility of
ndomyocardial biopsy remains uncertain and the procedure
s not routinely performed. However, the findings of the
urrent investigation suggest that the incorporation of gene
igure 3. Change in left ventricular ejection fraction (LVEF) at 12 months
R1 Tertile
ntermediate
TNFR1
(n  7)
High
TNFR1
(n  6) p Value
0.29  0.05 0.27  0.06 NS
0.37  0.15 0.33  0.09 0.02
0.37  0.13 0.31  0.09 0.003
0.08  0.13 0.06  0.07 0.02
0.08  0.12 0.04  0.10 0.01TNF
Iy tertiles of baseline Fas expression. Higher Fas expression is associated
ith less improvement in LVEF at 12 months, p  0.004.
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September 20, 2005:1036–42 Fas Expression in Recent-Onset Cardiomyopathyxpression profiles may significantly improve the predictive
alue of myocardial assessment.
The Fas/FasL system is involved in the pathogenesis of
utoimmune myocarditis (16) and peripartum cardiomyop-
thy (17). Elevated levels of soluble Fas and FasL have been
hown in patients with myocarditis (10) and chronic con-
estive heart failure (6–9), and have been found to predict
linical outcomes (11). The TNFR1 receptor, when acti-
ated by TNF-alpha, induces several cellular processes,
ncluding apoptosis (18). Patients with increased expression
f Fas and TNFR1 may be showing a more profound
esponse to myocardial injury, resulting in increased cell
eath and diminished potential for recovery. Alternatively,
hese patients may have undergone biopsy at a more
dvanced stage of disease progression, in which increase in
rogrammed cell death is evident. Whether increased ex-
ression represents a distinct response to injury or a simply
different stage of the inflammatory/apoptotic response
annot be determined by the current study.
Male gender was associated with higher Fas and TNFR1
xpression. The murine model of autoimmune disease
hows significant gender differences in the expression of
enes associated with programmed cell death (19). Testos-
erone stimulates apoptosis in vitro in renal tubular cells,
nd may contribute to the more rapid progression of
iabetic nephropathy in men (20). In a rat ischemia-
eperfusion model, reduction of androgens through surgical
astration or hormonal therapy decreases pro-inflammatory
nd pro-apoptotic gene expression and facilitates myocardial
ecovery (21). The tendency of androgens to stimulate
ytokine and pro-apoptotic gene expression would theoret-
cally limit myocardial recovery in men relative to women
nd may underlie the male predominance in idiopathic
ilated cardiomyopathy (22).
igure 4. Change in left ventricular ejection fraction (LVEF) at 12 months
y tertiles of baseline tumor necrosis factor receptor 1 (TNFR1) expression.
igher TNFR1 expression is associated with less improvement in LVEF
t six months, p  0.023.Plasma levels of TNF-alpha are elevated in patients with
l
new-onset cardiomyopathy and correlate with myocardial
xpression (19). The current study shows a strong correla-
ion between myocardial expression of Fas and TNF-alpha
onsistent with the role of TNF in initiating the apoptotic
athway. Despite this correlation, TNF-alpha and FasL
xpression were not predictive of recovery of left ventricular
unction, suggesting that receptor expression is more reflec-
ive of myocardial processes that lead to apoptosis than the
irculating ligands. Additionally, the role of TNF-alpha in
cute cardiomyopathy is complex; TNF-alpha plays a role in
ell survival and protection through induction of the tran-
cription factor nuclear factor kappa-beta (18). The overall
mpact of TNF expression on LV recovery may therefore
epresent a synthesis of these two competing roles: protec-
ion from viral injury and facilitation of apoptosis.
In acute viral myocarditis, cytokine expression and apo-
tosis may be beneficial and facilitate viral clearing. Al-
hough the current cohort is defined by the recent onset of
ymptoms, they seem to be beyond the stage of an acute
iral trigger. No patient was febrile at the time of endomyo-
ardial biopsy, all had normal white cell counts, and only
ne had histologic evidence of lymphocytic myocarditis.
he apparent negative impact of cytokine and apoptotic
yocardial expression in this cohort may reflect a later
ost-viral stage of this disorder, and the current study
annot address the potential protective role in acute viral
yocarditis.
There are several limitations to this study. Given the
imited myocardial tissue available, protein levels of Fas and
NFR1 were not assessed. In addition, immunohistochem-
stry quantifying apoptotic nuclei was not performed. Sol-
ble Fas and FasL were not assessed in the serum, and this
tudy cannot address the predictive value of these more
ccessible peripheral markers of apoptosis. We have previ-
igure 5. Change in left ventricular ejection fraction (LVEF) at 12
onths by tertiles of baseline Fas expression. Solid black lines 
edian; rectangles  quartile range; whiskers  total range excluding
utlier; filled circle  outlier. Higher Fas expression is associated with
ess improvement in LVEF at 12 months, p  0.011. TNFR1  tumor
ecrosis factor receptor 1.
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ial expression (23). In addition, as with routine histology,
iopsy studies of gene expression may be subject to sampling
rror because of regional variations. However, previous
tudies of myocardial gene expression in the right ventricle
eptum showed significant correlation with expression in the
eft ventricular free wall (24). Finally, patients in this study
ere part of a larger randomized trial of immune globulin
herapy, and we cannot rule out that an interaction with the
andomized therapy may have impacted the results. The
bsence of any impact of treatment of immune globulin on
ubsequent LVEF in the larger trial diminishes this possi-
ility (12).
This study is the first to suggest that the gene expression
rofile from an endomyocardial biopsy predicts subsequent
V recovery for patients with recent-onset cardiomyopathy.
ctivation of apoptotic pathways, as delineated by higher
as and TNFR1 expression, denotes a subset of patients
nlikely to recover LV function, whereas patients with
inimal Fas and TNFR1 expression experienced a dramatic
ncrease in LVEF during subsequent follow-up. Whether
atients with higher Fas and TNFR1 expression were
howing a differential response to injury or were captured at
later phase of their illness remains a question for further
tudy. In contrast to the role of the ligands TNF-alpha and
asL, high expression of the receptors Fas and TNFR1
eems to limit LV recovery and may represent targets for
herapeutic intervention.
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